Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial

IMPORTANCE: Faricimab, the first bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). OBJECTIVE: To assess the efficacy and safety of different doses and regimens of faricima...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahni, Jayashree, Dugel, Pravin U., Patel, Sunil S., Chittum, Mark E., Berger, Brian, del Valle Rubido, Marta, Sadikhov, Shamil, Szczesny, Piotr, Schwab, Dietmar, Nogoceke, Everson, Weikert, Robert, Fauser, Sascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393587/
https://www.ncbi.nlm.nih.gov/pubmed/32729888
http://dx.doi.org/10.1001/jamaophthalmol.2020.2685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393587/
https://www.ncbi.nlm.nih.gov/pubmed/32729888
http://dx.doi.org/10.1001/jamaophthalmol.2020.2685

Ejemplares similares